Pathway Financial Advisers LLC Has $271,000 Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Pathway Financial Advisers LLC increased its position in shares of Kenvue Inc. (NYSE:KVUE) by 19.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,697 shares of the company’s stock after acquiring an additional 2,040 shares during the period. Pathway Financial Advisers LLC’s holdings in Kenvue were worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of KVUE. Grove Bank & Trust raised its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue in the fourth quarter worth approximately $29,000. Riverview Trust Co bought a new position in Kenvue during the third quarter valued at approximately $30,000. Fortitude Family Office LLC lifted its stake in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after acquiring an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new position in shares of Kenvue during the 3rd quarter worth $35,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of Kenvue stock opened at $20.96 on Thursday. The firm has a fifty day moving average price of $21.41 and a two-hundred day moving average price of $22.03. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $40.19 billion, a PE ratio of 39.55, a price-to-earnings-growth ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts expect that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.91%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is presently 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several analyst reports. Canaccord Genuity Group lowered their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. UBS Group lowered their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Barclays reduced their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.